Kit for early diagnosis of young acute coronary syndrome based on plasma transcriptomics and application thereof
By analyzing the expression levels of specific proteins in plasma and combining machine learning methods, a risk scoring model for acute coronary syndrome in young people was established, which solved the problem of insufficient existing diagnostic methods and achieved early, accurate diagnosis and personalized treatment of acute coronary syndrome in young people.
Patent Information
- Application Number
- CN202510680127.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-05-26
- Publication Date
- 2025-09-19
AI Technical Summary
Existing diagnostic methods for acute coronary syndrome in young people mainly rely on clinical research and experience in middle-aged and elderly people, which makes them difficult to apply to young people. In addition, there is a lack of large-scale, multi-omics research, resulting in insufficient diagnostic standards and treatment plans, and an inability to effectively address the high mortality and disability rates of acute coronary syndrome in young people.
By analyzing the expression levels of twelve proteins in plasma, including FAM178B, ARVCF, SLC6A9, BNC2, DKK2, CLSTN3, SEMA6B, DAB2IP, LUC7L, NIPAL4, RBFOX3, and ST18, and combining random forest, LASSO regression, and XGBOOST machine learning methods, a risk scoring model for acute coronary syndrome in young people was established, providing a non-invasive and rapid early diagnosis method.
It has achieved early and accurate diagnosis of acute coronary syndrome in young people, improved the sensitivity and specificity of diagnosis, reduced mortality and disability rates, and provided personalized treatment plans.